Try our Advanced Search for more refined results
Life Sciences
-
December 15, 2025
Blank Rome Hires Baker McKenzie Litigator In DC
Blank Rome LLP has hired a Baker McKenzie litigator who focuses his practice on technology, life sciences, aerospace, government contracts and energy industry-related matters to join the team in Washington, D.C., as a partner, the firm announced Monday.
-
December 15, 2025
The Top Patent Decisions Of 2025
The Federal Circuit decided its first en banc utility patent case in years and expanded who can use the U.S. International Trade Commission, while both the appeals court and U.S. Patent and Trademark Office took on the eligibility of AI patents. Here's a look at the top patent decisions of 2025.
-
December 15, 2025
PTAB Creates New Prehearing Conference For AIA Reviews
The Patent Trial and Appeal Board has rolled out a change to its trial practice guide that will create a new prehearing conference 15 days prior to oral hearings under the America Invents Act in cases implemented by the U.S. Patent and Trademark Office director.
-
December 15, 2025
High Court Won't Review Doctor 'Upcoding' Acquittal Decision
The U.S. Supreme Court said Monday that it won't review a decision allowing a retrial of a Maryland doctor who was initially found guilty of a COVID-19 testing scheme but then secured an acquittal.
-
December 15, 2025
Supreme Court Declines Cannabis Ban Review
The U.S. Supreme Court on Monday declined to hear a case challenging the federal marijuana ban, leaving in place a high court precedent that has governed cannabis policy for 20 years.
-
December 15, 2025
Supreme Court Turns Down Entresto Patent Fight
The U.S. Supreme Court on Monday rejected a petition from MSN Pharmaceuticals Inc. claiming the Federal Circuit improperly applied what is known as after-arising technology when reviving a patent covering Novartis Pharmaceuticals Corp.'s blockbuster cardiovascular drug Entresto.
-
December 15, 2025
McDermott-Led Sobi To Buy US Gout Specialist For $1.5B
Swedish biopharma company Swedish Orphan Biovitrum AB said Monday that it has agreed to acquire Arthrosi Therapeutics Inc., a specialist in treatment for gout, for up to $1.5 billion in a deal guided by McDermott.
-
December 12, 2025
1st Circ. OKs Barring Medicaid Planned Parenthood Coverage
A First Circuit panel on Friday upheld the Trump administration's ban on Medicaid funding for Planned Parenthood, vacating a lower court's order that would've kept in place Medicaid reimbursements for Planned Parenthood clinics in 22 states.
-
December 12, 2025
Ore. Justices Rule Docs Can Be Liable For Nonpatient Deaths
Oregon's highest court ruled that medical professionals can be held liable if their negligence results in a nonpatient's death, settling a split between a trial and appeals court in a case over a cyclist struck and killed by a driver under the influence of prescription drugs.
-
December 12, 2025
Squires Institutes 7 AIA Reviews, Denies 12 Other Petitions
U.S. Patent and Trademark Office Director John Squires has instituted seven America Invents Act reviews in the second round of cases where he has found that patent challenges warrant consideration since taking over the institution process.
-
December 12, 2025
CooperSurgical Escapes Repeat Filshie Clip Claims In Conn.
Medical device maker CooperSurgical Inc. has scored a quick win on some women's claims that the Filshie Clip, a coated titanium birth control device, detached and migrated within their bodies, with a Connecticut state judge finding certain plaintiffs could not advance cases similar to claims they lost elsewhere.
-
December 12, 2025
Mississippi Litigator Joins Butler Snow From Adams & Reese
Butler Snow LLP announced that an experienced litigation and appellate attorney has joined the firm's healthcare practice in Ridgeland, Mississippi, after a stint with Adams & Reese LLP.
-
December 12, 2025
Fed. Circ. Says PTAB Was Right To Ax Tracking Patent Claims
The Federal Circuit on Friday refused to revive claims in a group of patents for tracking items during surgeries and other uses, rejecting challenges to how the Patent Trial and Appeal Board interpreted key claim terms.
-
December 12, 2025
Higgs Fletcher Forms White Collar, Regs Enforcement Team
San Diego-based law firm Higgs Fletcher & Mack LLP has launched a white collar crime and regulatory enforcement defense practice group, citing heightened regulatory scrutiny in the financial and healthcare sectors and rising enforcement risks for licensed professionals and institutions.
-
December 11, 2025
LA Bellwether Jury To Decide If J&J Hid Talc Risk For Decades
An attorney for one of two women who claim Johnson & Johnson's talcum products caused their ovarian cancer told a California jury Thursday in a bellwether trial's closing arguments that the company hid the health risks of talc for decades, while the company's attorney insisted the science is on their side.
-
December 11, 2025
DC Circ. Oversees FDA Fight Over Generic IBS Drug
Norwich Pharmaceuticals faced off against the U.S. Food and Drug Administration before the D.C. Circuit twice Thursday morning, both battles part of the drugmaker's five-year effort to bring a generic version of a prescription antibiotic used to treat irritable bowel syndrome to market.
-
December 11, 2025
Tracking Challenges To USPTO's Discretion Policy
Leaders at the U.S. Patent and Trademark Office have significantly altered the Patent Trial and Appeal Board playing field since March, making changes to institution reviews that have led to unprecedented levels of petition denials. A steady stream of companies has challenged those changes through mandamus petitions to the Federal Circuit, and here Law360 tracks where those petitions stand.
-
December 11, 2025
Pharmacies Battle For Coverage Of Opioid Lawsuit Claims
Publix Super Markets and a Georgia-based generic-drug wholesaler urged the Eleventh Circuit on Thursday to force their insurers to defend them in numerous lawsuits accusing the pharmacies of improperly distributing opioids, arguing their policies' coverage for "bodily injury" should include the suits.
-
December 11, 2025
NC County Sues DuPont, 3M, Tyco Over PFAS Contamination
A county in southeastern North Carolina is suing 3M Co., DuPont de Nemours Inc., the Chemours Co., Tyco Fire Products LP and other companies, alleging that they knowingly sold products containing PFAS, or "forever chemicals," that have contaminated county land.
-
December 11, 2025
Elevance Health Adds Former Pfizer GC To Its Board
Insurer Elevance Health has appointed former Pfizer Inc. general counsel Amy Schulman, currently a managing partner of Polaris Partners, to serve on its board of directors.
-
December 11, 2025
Sidley Guides Diagnostic Imaging Firm Lumexa's $463M IPO
Private equity-backed diagnostic imaging provider Lumexa Imaging Holdings Inc., led by Sidley Austin LLP, began trading Thursday on the Nasdaq Global Select Market after pricing a $463 million initial public offering.
-
December 11, 2025
6th Circ. Panel Shows No Leanings On PBM Jurisdiction Fight
A Sixth Circuit appeals panel gave few hints Thursday on whether it would send back to state court a lawsuit from Ohio alleging that pharmacy benefit managers were driving up prescription prices through rebate schemes.
-
December 11, 2025
4 Firms Guide As Arcline Exits Medical Tech Co. In $685M Deal
Perimeter Solutions Inc. has agreed to acquire Medical Manufacturing Technologies LLC from Arcline Investment Management for approximately $685 million in cash, including certain tax benefits.
-
December 10, 2025
Diagnostic Co. Agrees To Oversight Reforms In Derivative Suit
A California federal judge has granted preliminary approval to a deal ending shareholder derivative claims that diagnostics company CareDx's executives and directors damaged the company by concealing its scheme to inflate its testing services revenue.
-
December 10, 2025
Teva Pulls 200 Patents From Orange Book Amid FTC Probe
The Federal Trade Commission said Wednesday an investigation it conducted into Teva Pharmaceuticals prompted the company to remove over 200 patents from the U.S. Food and Drug Administration's Orange Book.
Expert Analysis
-
Trending At The PTAB: A Potential Barrier To Serial Challenges
New rules proposed by the U.S. Patent and Trademark Office may appear similar to previous rules at first glance, but are actually much broader in how they would limit petitioners' ability to challenge a patent more than once, say attorneys at Finnegan.
-
What's Changing For Cos. In New Calif. Hazardous Waste Plan
While the latest hazardous waste management plan from California's Department of Toxic Substances Control still awaits final approval, companies can begin aligning internal systems now with the plan's new requirements for environmental justice, waste and disposal reduction, waste criteria, and capacity planning, says Thierry Montoya at Frost Brown.
-
Fed. Circ. In September: The Printed Matter Doctrine Expands
The Federal Circuit’s recent decision in Bayer v. Mylan represents an extension of the doctrine that adding new words to an existing product or method will not support patentability unless there is a functional relationship, bringing new considerations for both patent holders and challengers, say attorneys at Knobbe Martens.
-
Justices' LabCorp Punt Leaves Deeper Class Cert. Circuit Split
In its ruling in LabCorp v. Davis, the U.S. Supreme Court left unresolved a standing-related class certification issue that has plagued class action jurisprudence for years — and subsequent conflicting decisions among federal circuit courts have left district courts and litigants struggling with conflicting and uncertain standards, say attorneys at Cozen O'Connor.
-
Series
Practicing Stoicism Makes Me A Better Lawyer
Practicing Stoicism, by applying reason to ignore my emotions and govern my decisions, has enabled me to approach challenging situations in a structured way, ultimately providing advice singularly devoted to a client's interest, says John Baranello at Moses & Singer.
-
Broader Eligibility For AI-Related Patents May Be Coming
A series of recent developments from the U.S. Patent and Trademark Office appears to signal that claims involving improvement in the operation of a machine learning model are now more likely to be considered patent-eligible, and that patent examiners may focus on questions of novelty and nonobviousness and less so on subject matter eligibility, say attorneys at Kilpatrick.
-
Series
The Biz Court Digest: Texas, One Year In
A year after the Texas Business Court's first decision, it's clear that Texas didn't just copy Delaware and instead built something uniquely its own, combining specialization with constitutional accountability and creating a model that looks forward without losing touch with the state's democratic and statutory roots, says Chris Bankler at Jackson Walker.
-
AI Product Safety Insights May Expand Foreseeability
Product liability law has long held that companies are responsible for risks they knew about or should have known about — and with AI systems now able to assess and predict hazards during the design process, companies should expect that courts will likely treat such hazards as foreseeable, says Donald Fountain at Clark Fountain.
-
Series
Law School's Missed Lessons: Educating Your Community
Nearly two decades prosecuting scammers and elder fraud taught me that proactively educating the public about the risks they face and the rights they possess is essential to building trust within our communities, empowering otherwise vulnerable citizens and preventing wrongdoers from gaining a foothold, says Roger Handberg at GrayRobinson.
-
Organ Transplant System Reforms Mark Regulatory Overhaul
Recent oversight, enforcement and operational developments in the U.S. organ procurement and transplantation system, alongside challenges like the federal shutdown, highlight heightened regulatory scrutiny and the need for compliance to maintain public trust, say attorneys at Hall Render.
-
Adapting To USPTO's Reduction Of Examiner Interview Time
Reported changes to the U.S. Patent and Trademark Office's examiner performance appraisal plan will likely make interviews scarcer throughout the application process, potentially influencing patent allowance rates and increasing the importance of approaching each interview with a clear agenda and well-defined goals, say attorneys at Polsinelli.
-
Federal Grantees May Soon Face More Limitations On Speech
If courts accept the administration’s new interpretation of preexisting case law, which attempts to graft onto grant recipients the existing limitations on government contractors' free speech, a more deferential standard may soon apply in determining whether an agency’s refusal or termination of a grant was in violation of the First Amendment, say attorneys at Venable.
-
5 Crisis Lawyering Skills For An Age Of Uncertainty
As attorneys increasingly face unprecedented and pervasive situations — from prosecutions of law enforcement officials to executive orders targeting law firms — they must develop several essential competencies of effective crisis lawyering, says Ray Brescia at Albany Law School.
-
Anticipating FTC's Shift On Unfair Competition Enforcement
As the Federal Trade Commission signals that it will continue to challenge unfair or deceptive acts and practices under Section 5 of the FTC Act, but with higher evidentiary standards, attorneys counseling healthcare, technology, energy or pharmaceuticals clients should note several practice tips, says Thomas Stratmann at George Mason University.
-
Insights From Recent Cases On Navigating Snap Removal
Snap removal, which allows defendants to transfer state court cases to federal court before a forum defendant is properly joined and served, is viewed differently across federal circuits — but keys to making it work can be drawn from recent decisions critiquing the practice, say attorneys at Perkins Coie.